{"id":"NCT03358875","sponsor":"BeiGene","briefTitle":"Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-30","primaryCompletion":"2021-07-15","completion":"2024-01-18","firstPosted":"2017-12-02","resultsPosted":"2025-02-10","lastUpdate":"2025-02-10"},"enrollment":805,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Tislelizumab","otherNames":["BGB-A317","TEVIMBRA®"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"Tislelizumab","type":"EXPERIMENTAL"},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.","primaryOutcome":{"measure":"Overall Survival (OS) in All Participants (Co-primary Endpoint)","timeFrame":"From randomization to the data cutoff date of 10 August 2020; up to 32.4 months","effectByArm":[{"arm":"Tislelizumab","deltaMin":17.2,"sd":null},{"arm":"Docetaxel","deltaMin":11.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":121,"countries":["Brazil","Bulgaria","China","Lithuania","Mexico","New Zealand","Poland","Russia","Slovakia","Turkey (Türkiye)"]},"refs":{"pmids":["36184068","37587845"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":192,"n":534},"commonTop":["Anaemia","Alanine aminotransferase increased","Cough","Decreased appetite","Aspartate aminotransferase increased"]}}